- Home
- NAVI vs IMCR Comparison
NAVI vs IMCR Comparison
Compare NAVI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAVI
- IMCR
- Stock Information
- Founded
- NAVI 1973
- IMCR 2008
- Country
- NAVI United States
- IMCR United Kingdom
- Employees
- NAVI N/A
- IMCR N/A
- Industry
- NAVI Investment Bankers/Brokers/Service
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAVI Finance
- IMCR Health Care
- Exchange
- NAVI Nasdaq
- IMCR Nasdaq
- Market Cap
- NAVI 1.7B
- IMCR 1.7B
- IPO Year
- NAVI N/A
- IMCR 2021
- Fundamental
- Price
- NAVI $14.74
- IMCR $29.05
- Analyst Decision
- NAVI Sell
- IMCR Buy
- Analyst Count
- NAVI 8
- IMCR 13
- Target Price
- NAVI $14.63
- IMCR $65.18
- AVG Volume (30 Days)
- NAVI 898.7K
- IMCR 246.4K
- Earning Date
- NAVI 01-29-2025
- IMCR 11-06-2024
- Dividend Yield
- NAVI 4.40%
- IMCR N/A
- EPS Growth
- NAVI N/A
- IMCR N/A
- EPS
- NAVI 0.70
- IMCR N/A
- Revenue
- NAVI $1,036,000,000.00
- IMCR $296,312,000.00
- Revenue This Year
- NAVI N/A
- IMCR $29.19
- Revenue Next Year
- NAVI $1.01
- IMCR $12.56
- P/E Ratio
- NAVI $20.86
- IMCR N/A
- Revenue Growth
- NAVI N/A
- IMCR 25.09
- 52 Week Low
- NAVI $13.71
- IMCR $28.17
- 52 Week High
- NAVI $19.44
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- NAVI 43.14
- IMCR 33.78
- Support Level
- NAVI $14.52
- IMCR $28.17
- Resistance Level
- NAVI $15.26
- IMCR $29.91
- Average True Range (ATR)
- NAVI 0.35
- IMCR 1.34
- MACD
- NAVI -0.06
- IMCR -0.30
- Stochastic Oscillator
- NAVI 12.74
- IMCR 18.30
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance and business processing solutions that simplify complex programs and help millions of people achieve success. It operates business in three segments: Federal Education Loans, Consumer Lending and Business Processing.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.